

Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference -- SAN DIEGO, Jan. 3, 2012 /PRNewswire/ --
Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: [ OPTR ]) today announced that the Company will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 8:30 AM Pacific Time.
(Logo: [ http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ] )
A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at [ www.optimerpharma.com ]. Replays of the presentation will be available at the same location for 30 days following the presentation.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at [ http://www.optimerpharma.com ].
Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736
Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005
SOURCE Optimer Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.optimerpharma.com ]